Disposition of 4017 shares by Kck Ltd. of Neuropace at 6.497 subject to Rule 16b-3

NPCE Stock  USD 13.52  0.25  1.82%   
About 55% of Neuropace's investor base is interested to short. The analysis of overall sentiment of trading Neuropace stock suggests that many investors are impartial at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Neuropace 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
Disposition of 4017 common stock at 6.497 of Neuropace by Kck Ltd. on 15th of October 2024. This event was filed by Neuropace with SEC on 2024-10-15. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Neuropace's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Neuropace's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Neuropace Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neuropace Historical Investor Sentiment

Investor biases related to Neuropace's public news can be used to forecast risks associated with an investment in Neuropace. The trend in average sentiment can be used to explain how an investor holding Neuropace can time the market purely based on public headlines and social activities around Neuropace. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Neuropace's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Neuropace and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Neuropace news discussions. The higher the estimate score, the more favorable the investor's outlook on Neuropace.

Neuropace Maximum Pain Price Across May 16th 2025 Option Contracts

Neuropace's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Neuropace close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Neuropace's options.

Neuropace Fundamental Analysis

We analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Neuropace is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Neuropace Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuropace stock to make a market-neutral strategy. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics with similar companies.

Peers

Neuropace Related Equities

ANIKAnika Therapeutics   1.61   
0%
19.0%
SRDXSurModics   1.51   
0%
18.0%
CNMDCONMED   1.24   
0%
15.0%
ITGRInteger Holdings   0.60   
0%
7.0%
CVRXCVRx   0.46   
0%
5.0%
NVRONevro Corp   0.17   
2.0%
0%
FNAParagon 28   0.31   
3.0%
0%
ELMDElectromed   0.78   
9.0%
0%
IRMDIradimed   0.96   
11.0%
0%
KIDSOrthopediatrics Corp   2.30   
27.0%
0%
LUNGPulmonx Corp   2.69   
32.0%
0%
GKOSGlaukos Corp   3.00   
36.0%
0%
OFIXOrthofix Medical   3.53   
42.0%
0%
AORTArtivion   8.22   
100.0%
0%

Complementary Tools for Neuropace Stock analysis

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules